The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant
Open accessAbstract
bacteremia occurred after they had undergone FMT in two independent clinical trials; both cases were linked to the same stool donor by means of genomic sequencing. One of the patients died. Enhanced donor screening to limit the transmission of microorganisms that could lead to adverse infectious events and continued vigilance to define the benefits and risks of FMT across different patient populations are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FMT may also carry the risk of unintended introduction of pathogens and antibiotic-resistant microbes into the recipients.749,750”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [749]
In the citing paper
“In 2019, it was reported that in two independent clinical trials, two patients developed bacteremia with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli after receiving FMT from the same donor, and one patient died [136].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · cites this paper as [136]
In the citing paper
“This issue has become extremely timely after the transmission of an extended-spectrum b -lactamase-producing Escherichia coli strain from a stool donor to two immunocompromised recipients who developed bacteremia, with a fatal outcome in one case. 46”
From Key determinants of success in fecal microbiota transplantation: From microbiome to clinic (2023) · cites this paper as [46]
In the citing paper
“Indeed, two cases of MDR bacteria transmission with life-threatening complications have been described in patients with cirrhosis and hematological malignancy after repeated FMT. 46”
From Key determinants of success in fecal microbiota transplantation: From microbiome to clinic (2023) · cites this paper as [46]
In the citing paper
“Although FMT is generally recognized as safe, with no or limited side effects,33 unexpected toxicity has been reported, e.g., extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli bacteremia in two patients who received FMT.34”
From Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors (2024) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
European consensus conference on faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C. P., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy149 · Cited by 1,163
Beceiro, A., Tomás, M., & Bou, G. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00059-12 · Cited by 1,118
Kassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904
Pathological bacterial translocation in liver cirrhosis
Wiest, R., Lawson, M. A., & Geuking, M. B. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.044 · Cited by 826
Youngster, I., Russell, G. H., Pindar, C., Ziv-Baran, T., Sauk, J., & Hohmann, E. L. (2014) · JAMA · doi:10.1001/jama.2014.13875 · Cited by 629
Self-citationSchürch, A. C., Arredondo-Alonso, S., Willems, R. J. L., & Goering, R. V. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.12.016 · Cited by 534
Mullish, B. H., Quraishi, M. N., Segal, J. P., McCune, V. L., Baxter, M., Marsden, G. L., Moore, D., Colville, A., Bhala, N. B., Iqbal, T. H., et al. (2018) · Gut · doi:10.1136/gutjnl-2018-316818 · Cited by 344
Research works printed but not linked: 1
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: CLSI supplement M100. 29th ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2019.
Cited by
Sorted by citations
Gut microbial metabolites as multi-kingdom intermediates
Krautkramer, K. A., Fan, J., & Bäckhed, F. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0438-4 · Cited by 1,398
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
The gut–liver axis and gut microbiota in health and liver disease
Hsu, C. L., & Schnabl, B. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00904-3 · Cited by 737
Johnson, S., Lavergne, V., Skinner, A. M., Gonzales-Luna, A. J., Garey, K. W., Kelly, C. P., & Wilcox, M. H. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab549 · Cited by 696
Metadata
- Authors
- DeFilipp, Z., Bloom, P. P., Torres Soto, M., Mansour, M. K., Sater, M. R. A., Huntley, M. H., Turbett, S., Chung, R. T., Chen, Y.-B., & Hohmann, E. L.
- Affiliations
- Harvard University (US)
- From the Blood and Marrow Transplant Program (Z.D., Y.-B.C.), the Liver Center, Division of Gastroenterology (P.P.B., R.T.C.), and the Division of Infectious Diseases (M.T.S., M.K.M., S.T., E.L.H.), Massachusetts General Hospital, Harvard Medical School (Z.D., P.P.B., M.T.S., M.K.M., S.T., R.T.C., Y.-B.C., E.L.H.), and Day Zero Diagnostics (M.R.A.S., M.H.H.) — all in Boston.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-11-21
- Volume
- 381
- Issue
- 21
- Pages
- 2043-2050
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2982566732
- Cited by
- 1,281
- References
- 26
- Citations by year
- 2026: 202 · 2025: 160 · 2024: 158 · 2023: 175 · 2022: 169 · 2021: 184 · 2020: 222 · 2019: 10
- FWCI
- 112.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Massachusetts General Hospital
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- drug-resistant Escherichia coli, bacteremia, fecal microbiota transplantation, donor screening, genome sequencing
- MeSH terms
- Fecal Microbiota Transplantation, Aged, beta-Lactamases, Escherichia coli, Feces, Hepatic Encephalopathy, Humans, Male, Myelodysplastic Syndromes, Bacteremia, Fatal Outcome, Drug Resistance, Bacterial, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
